<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03772028</url>
  </required_header>
  <id_info>
    <org_study_id>M17OVH</org_study_id>
    <nct_id>NCT03772028</nct_id>
  </id_info>
  <brief_title>Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)</brief_title>
  <acronym>OVHIPEC-2</acronym>
  <official_title>Phase III Randomized Clinical Trial for Stage III Epithelial Ovarian Cancer Randomizing Between Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or
      without hyperthermic intraperitoneal chemotherapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to prove that treatment with primary cytoreductive surgery in
      combination with HIPEC (treatment arm) improves outcome compared to primary cytoreductive
      surgery without HIPEC (standard arm) with acceptable morbidity, in patients with FIGO stage
      III epithelial ovarian cancer who are eligible for primary cytoreductive surgery with no
      residual disease, or residual disease up to 2.5 mm.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized controlled, open-label, multicenter phase III trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>1 year after last patient last visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>recurrence-free survival</measure>
    <time_frame>1 year after last patient last visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>30 days after end of treatment</time_frame>
    <description>toxicity of extra treatment compared standaard treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cost evaluation</measure>
    <time_frame>1 year after lplv</time_frame>
    <description>cost evaluation based measured by quality adjusted life year</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">538</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>conventional surgery</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Primary cytoreductive surgery without HIPEC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIPEC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Primary cytoreductive surgery with HIPEC with cisplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>HIPEC with cisplatin after cytoreductive surgery</description>
    <arm_group_label>HIPEC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  candidate for primary CRS

          -  histological or cytological proven FIGO stage III primary epithelial ovarian,
             fallopian tube, or extra-ovarian cancer

        Exclusion Criteria:

          -  history of previous malignancies within 5 years prior to inclusion

          -  FIGO stage IV disease

          -  complete primary cytoreduction is impossible

          -  prior treatment for the current malignancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>ovarian cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Willemien van Driel, MD, PhD</last_name>
    <phone>0205129111</phone>
    <email>w.v.driel@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simone Koole</last_name>
    <phone>0205129111</phone>
    <email>s.koole@nki.nl</email>
  </overall_contact_backup>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>September 21, 2018</study_first_submitted>
  <study_first_submitted_qc>December 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2018</study_first_posted>
  <last_update_submitted>May 22, 2019</last_update_submitted>
  <last_update_submitted_qc>May 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ovarian cancer</keyword>
  <keyword>HIPEC</keyword>
  <keyword>OVHIPEC</keyword>
  <keyword>primary debulking</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

